AZATHIOPRINE-50 TABLET
Country: Kanada
Lingwa: Ingliż
Sors: Health Canada
Karatteristiċi tal-prodott
(SPC)
11-02-2020
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
AZATHIOPRINE
Disponibbli minn:
PRO DOC LIMITEE
Kodiċi ATC:
L04AX01
INN (Isem Internazzjonali):
AZATHIOPRINE
Dożaġġ:
50MG
Għamla farmaċewtika:
TABLET
Kompożizzjoni:
AZATHIOPRINE 50MG
Rotta amministrattiva:
ORAL
Unitajiet fil-pakkett:
100
Tip ta 'preskrizzjoni:
Prescription
Żona terapewtika:
IMMUNOSUPPRESSIVE AGENTS
Sommarju tal-prodott:
Active ingredient group (AIG) number: 0101830001; AHFS:
L-istatus ta 'awtorizzazzjoni:
CANCELLED POST MARKET
Data ta 'l-awtorizzazzjoni:
2023-07-10
Karatteristiċi tal-prodott
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AZATHIOPRINE-50
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
PRO DOC LTÉE
Date of Revision:
2925, Boul. Industriel,
February 11, 2020
Laval, Quebec
H7L 3W9
Submission Control No.: 235658
_AZATHIOPRINE-50 Product Monograph _
_ _
Page 2 of 29
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
9
DRUG INTERACTIONS
............................................................................................................................
11
DOSAGE AND ADMINISTRATION
........................................................................................................
12
OVERDOSAGE
..........................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
13
STORAGE AND STABILITY
....................................................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................
Aqra d-dokument sħiħ
